AAV9 vector-based Smad7 gene therapy (Genethon)

N/A

Report date: 2025/01/26 18:11:27

Base Information

Drug NameAAV9 vector-based Smad7 gene therapy (Genethon)
Drug Alias NameSmad7 gene therapy (adeno-associated viral vector) (Genethon)
ClassificationBiologics
Mechanisms of ActionMothers against decapentaplegic homolog 7 inhibitors
TargetsMothers against decapentaplegic homolog 7
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenethon
China Registration ClassN/A

Develop Information

Active CompaniesGenethon
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A